Streamlined Resin Y90 Radiation Segmentectomy for Small HCC
Active, not recruiting · NCT06618300
Conditions: Hepatocellular Carcinoma (HCC)
At a glance
- Research payments reported, 2025
- $68,252
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- UNC Lineberger Comprehensive Cancer Center (with Sirtex, Wodburn, MA)
- Dates
- Started 2024-11-06; completion 2027-12-31
- Results posted
- Not yet
This single-arm feasibility study evaluating the safety and efficacy of streamlining Yttrium-90 (Y90) radioembolization workflow for patients with small Hepatocellular Carcinoma (\<5cm) that have no aggressive features on baseline imaging. This study aims to recruit N=30 patients prospectively and consolidate the current workflow of 2 days of procedures (1st-day mapping angiography followed by nuclear medicine hepatic lung shunt fraction (LSF) calculation using Tc99-MAA planar and SPECT/CT, and 2nd-day Y90 radioembolization followed by nuclear medicine Y90 SPECT/CT) into 1-day procedure. Several studies have shown that hepatic LSF for HCC tumors smaller than 5cm in the absence of macro…
From ClinicalTrials.gov, last updated 2026-08-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sirtex Medical Inc reported $68,252 in research payments for this study in 2025 (5 payments).
Products named: Sir-Spheres Microspheres
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.